Research Analysts’ Recent Ratings Updates for Enanta Pharmaceuticals (ENTA)

Enanta Pharmaceuticals (NASDAQ: ENTA) recently received a number of ratings updates from brokerages and research firms:

  • 7/14/2022 – Enanta Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
  • 7/6/2022 – Enanta Pharmaceuticals was upgraded by analysts at Evercore ISI from an “in-line” rating to an “outperform” rating. They now have a $62.00 price target on the stock.
  • 7/4/2022 – Enanta Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
  • 7/1/2022 – Enanta Pharmaceuticals had its price target raised by analysts at Royal Bank of Canada from $64.00 to $67.00. They now have a “sector perform” rating on the stock.
  • 6/23/2022 – Enanta Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
  • 6/22/2022 – Enanta Pharmaceuticals had its “buy” rating reaffirmed by analysts at JMP Securities. They now have a $103.00 price target on the stock.
  • 6/14/2022 – Enanta Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
  • 6/3/2022 – Enanta Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
  • 5/25/2022 – Enanta Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.

Enanta Pharmaceuticals Trading Up 0.6 %

NASDAQ ENTA opened at $51.27 on Thursday. The firm has a market capitalization of $1.06 billion, a P/E ratio of -9.29 and a beta of 0.53. The business has a fifty day simple moving average of $45.13 and a 200 day simple moving average of $58.76. Enanta Pharmaceuticals, Inc. has a 12 month low of $37.59 and a 12 month high of $102.00.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) last announced its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($1.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.20). The business had revenue of $18.72 million during the quarter, compared to the consensus estimate of $20.40 million. Enanta Pharmaceuticals had a negative net margin of 122.68% and a negative return on equity of 28.80%. During the same quarter last year, the company earned ($1.09) EPS. As a group, sell-side analysts predict that Enanta Pharmaceuticals, Inc. will post -5.56 EPS for the current fiscal year.

Institutional Trading of Enanta Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio boosted its position in shares of Enanta Pharmaceuticals by 35.6% during the fourth quarter. Strs Ohio now owns 14,100 shares of the biotechnology company’s stock valued at $1,054,000 after purchasing an additional 3,700 shares in the last quarter. Everence Capital Management Inc. bought a new stake in Enanta Pharmaceuticals during the fourth quarter valued at about $319,000. Allspring Global Investments Holdings LLC bought a new stake in Enanta Pharmaceuticals during the fourth quarter valued at about $1,113,000. Yousif Capital Management LLC bought a new stake in Enanta Pharmaceuticals during the fourth quarter valued at about $1,199,000. Finally, Robeco Institutional Asset Management B.V. bought a new stake in Enanta Pharmaceuticals during the fourth quarter valued at about $64,000. Hedge funds and other institutional investors own 98.87% of the company’s stock.

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

Featured Articles

Receive News & Ratings for Enanta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.